A case-control teratological study of vaginal natamycin treatment during pregnancy

E. Czeizel, Zoltán Kazy, Peter Vargha

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The aim of this study was to investigate the teratogenicity of vaginal natamycin treatment during pregnancy, because the data of human epidemiological studies have not been published. Pair analysis of cases with congenital abnormalities and matched healthy controls was carried out. The population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 included as total, 38,151 pregnant women who delivered newborn infants without any defects (control group) and 22,843 pregnant women who had fetuses or newborns with congenital abnormalities. 62 (0.27%) and 98 (0.26%) pregnant women were treated with the natamycin in the case and control groups, respectively (crude OR 1.1 with 95% CI: 0.8-1.5). A teratogenic potential of vaginal natamycin treatment during the second and third months of pregnancy, the critical period of most major congenital abnormalities, was not indicated in the case-control pair analysis (adjusted OR 0.9 with 95% CI: 0.4-1.8). A somewhat higher mean birth weight (72 g) was found in control newborn infants born to mothers with natamycin treatment compared with the data of control newborn infants without this treatment (adjusted P = 0.01), though mean gestational age was shorter. The conclusion of this study is that the treatment with vaginal natamycin during pregnancy presents no detectable teratogenic risk to the fetus.

Original languageEnglish
Pages (from-to)387-391
Number of pages5
JournalReproductive Toxicology
Volume17
Issue number4
DOIs
Publication statusPublished - Jul 2003

Fingerprint

Natamycin
Case-Control Studies
Pregnancy
Newborn Infant
Pregnant Women
Fetus
Therapeutics
Control Groups
Birth Weight
Gestational Age
Epidemiologic Studies
Mothers
Population
Defects

Keywords

  • Birth weight
  • Case-control study
  • Congenital abnormalities
  • Human teratogenic potential
  • Natamycin

ASJC Scopus subject areas

  • Toxicology

Cite this

A case-control teratological study of vaginal natamycin treatment during pregnancy. / Czeizel, E.; Kazy, Zoltán; Vargha, Peter.

In: Reproductive Toxicology, Vol. 17, No. 4, 07.2003, p. 387-391.

Research output: Contribution to journalArticle

Czeizel, E. ; Kazy, Zoltán ; Vargha, Peter. / A case-control teratological study of vaginal natamycin treatment during pregnancy. In: Reproductive Toxicology. 2003 ; Vol. 17, No. 4. pp. 387-391.
@article{3c0d1b3d4ace43e8aca80e08be07e68b,
title = "A case-control teratological study of vaginal natamycin treatment during pregnancy",
abstract = "The aim of this study was to investigate the teratogenicity of vaginal natamycin treatment during pregnancy, because the data of human epidemiological studies have not been published. Pair analysis of cases with congenital abnormalities and matched healthy controls was carried out. The population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 included as total, 38,151 pregnant women who delivered newborn infants without any defects (control group) and 22,843 pregnant women who had fetuses or newborns with congenital abnormalities. 62 (0.27{\%}) and 98 (0.26{\%}) pregnant women were treated with the natamycin in the case and control groups, respectively (crude OR 1.1 with 95{\%} CI: 0.8-1.5). A teratogenic potential of vaginal natamycin treatment during the second and third months of pregnancy, the critical period of most major congenital abnormalities, was not indicated in the case-control pair analysis (adjusted OR 0.9 with 95{\%} CI: 0.4-1.8). A somewhat higher mean birth weight (72 g) was found in control newborn infants born to mothers with natamycin treatment compared with the data of control newborn infants without this treatment (adjusted P = 0.01), though mean gestational age was shorter. The conclusion of this study is that the treatment with vaginal natamycin during pregnancy presents no detectable teratogenic risk to the fetus.",
keywords = "Birth weight, Case-control study, Congenital abnormalities, Human teratogenic potential, Natamycin",
author = "E. Czeizel and Zolt{\'a}n Kazy and Peter Vargha",
year = "2003",
month = "7",
doi = "10.1016/S0890-6238(03)00041-8",
language = "English",
volume = "17",
pages = "387--391",
journal = "Reproductigve Toxicoloy",
issn = "0890-6238",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - A case-control teratological study of vaginal natamycin treatment during pregnancy

AU - Czeizel, E.

AU - Kazy, Zoltán

AU - Vargha, Peter

PY - 2003/7

Y1 - 2003/7

N2 - The aim of this study was to investigate the teratogenicity of vaginal natamycin treatment during pregnancy, because the data of human epidemiological studies have not been published. Pair analysis of cases with congenital abnormalities and matched healthy controls was carried out. The population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 included as total, 38,151 pregnant women who delivered newborn infants without any defects (control group) and 22,843 pregnant women who had fetuses or newborns with congenital abnormalities. 62 (0.27%) and 98 (0.26%) pregnant women were treated with the natamycin in the case and control groups, respectively (crude OR 1.1 with 95% CI: 0.8-1.5). A teratogenic potential of vaginal natamycin treatment during the second and third months of pregnancy, the critical period of most major congenital abnormalities, was not indicated in the case-control pair analysis (adjusted OR 0.9 with 95% CI: 0.4-1.8). A somewhat higher mean birth weight (72 g) was found in control newborn infants born to mothers with natamycin treatment compared with the data of control newborn infants without this treatment (adjusted P = 0.01), though mean gestational age was shorter. The conclusion of this study is that the treatment with vaginal natamycin during pregnancy presents no detectable teratogenic risk to the fetus.

AB - The aim of this study was to investigate the teratogenicity of vaginal natamycin treatment during pregnancy, because the data of human epidemiological studies have not been published. Pair analysis of cases with congenital abnormalities and matched healthy controls was carried out. The population-based data set of the Hungarian Case-Control Surveillance of Congenital Abnormalities between 1980 and 1996 included as total, 38,151 pregnant women who delivered newborn infants without any defects (control group) and 22,843 pregnant women who had fetuses or newborns with congenital abnormalities. 62 (0.27%) and 98 (0.26%) pregnant women were treated with the natamycin in the case and control groups, respectively (crude OR 1.1 with 95% CI: 0.8-1.5). A teratogenic potential of vaginal natamycin treatment during the second and third months of pregnancy, the critical period of most major congenital abnormalities, was not indicated in the case-control pair analysis (adjusted OR 0.9 with 95% CI: 0.4-1.8). A somewhat higher mean birth weight (72 g) was found in control newborn infants born to mothers with natamycin treatment compared with the data of control newborn infants without this treatment (adjusted P = 0.01), though mean gestational age was shorter. The conclusion of this study is that the treatment with vaginal natamycin during pregnancy presents no detectable teratogenic risk to the fetus.

KW - Birth weight

KW - Case-control study

KW - Congenital abnormalities

KW - Human teratogenic potential

KW - Natamycin

UR - http://www.scopus.com/inward/record.url?scp=0038780050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038780050&partnerID=8YFLogxK

U2 - 10.1016/S0890-6238(03)00041-8

DO - 10.1016/S0890-6238(03)00041-8

M3 - Article

C2 - 12849848

AN - SCOPUS:0038780050

VL - 17

SP - 387

EP - 391

JO - Reproductigve Toxicoloy

JF - Reproductigve Toxicoloy

SN - 0890-6238

IS - 4

ER -